The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.
Woman of any age
Currently or recently pregnant
Consent to participate
Authorization for her HCP(s) to provide data to the registry
Occurrence of pregnancy outcome prior to first contact with the registry coordination center (retrospectively enrolled)
Exposure to known teratogens and/or investigational medications during pregnancy
Lost to follow-up
Sumitomo Pharma Switzerland GmbH
Lead sponsor